Showing results (61-70 of 266) with videos related to
Sort By:
Pageof 27
Best Practice & Research. Clinical Endocrinology & Metabolism|December 23, 2003
Disorders of phosphate metabolism--pathomechanisms and management of hypophosphataemic disordersEberhard Ritz, Volker Haxsen, Martin ZeierSeminars in Dialysis|April 16, 2002
Cardiovascular abnormalities and hypertension in the elderly dialysis patientRalf Dikow, Martin Zeier, Eberhard RitzJournal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|January 6, 2009
Role of sodium intake in the progression of chronic kidney diseaseEberhard Ritz, Nadezda Koleganova, Grzegorz PiechaCurrent Opinion in Nephrology and Hypertension|October 10, 2009
Vasculotropic effects of calcimimeticsNadezda Koleganova, Grzegorz Piecha, Eberhard RitzNature Reviews. Nephrology|February 27, 2013
Vasopressin: a novel target for the prevention and retardation of kidney disease?Lise Bankir, Nadine Bouby, Eberhard RitzCardiology Clinics|August 9, 2005
Pathophysiology of cardiovascular disease and renal failureRalf Dikow, Martin Zeier, Eberhard RitzPolskie Archiwum Medycyny Wewnetrznej|September 25, 2009
Dyslipidemia in chronic kidney disease: pathogenesis and interventionGrzegorz Piecha, Marcin Adamczak, Eberhard RitzSeminars in Dialysis|July 17, 2008
Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patientsOliver Vonend, L Christian Rump, Eberhard RitzJournal of the American Society of Nephrology : JASN|July 26, 2002
Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levelsAndrew G Bostom, Florian Kronenberg, Eberhard RitzJournal of the American Society of Nephrology : JASN|March 28, 2006
Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortalityClaus Peter Schmitt, Tobias Odenwald, Eberhard RitzPageof 27